Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members

Details for Australian Patent Application No. 2009221164 (hide)

Owner Novartis AG

Inventors Garcia-Echeverria, Carlos; Maira, Sauveur-Michel

Agent Davies Collison Cave

Pub. Number AU-B-2009221164

PCT Pub. Number WO2009/109605

Priority 08152326.8 05.03.08 EP

Filing date 4 March 2009

Wipo publication date 11 September 2009

Acceptance publication date 26 July 2012

International Classifications

A61K 45/06 Medicinal preparations containing active ingredients not provided for in groups

A61K 31/5377

A61P 35/00 Antineoplastic agents

Event Publications

2 September 2010 PCT application entered the National Phase

  PCT publication WO2009/109605 Priority application(s): WO2009/109605

26 July 2012 Application Accepted

  Published as AU-B-2009221164

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009221166-Foams having high flame resistance and low density

2009221155-Nicorandil carriers with enhanced stability